MedTrace Logo

Lung Bacteriobiota and Influenza Mortality

NCT04131296 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 64

Last updated 2019-11-01

No results posted yet for this study

Summary

Influenza is a potentially lethal disease still responsible for thousands excess deaths both in Europe and the United States. Despite the use of neuraminidase inhibitors, its treatment is mostly based on symptomatic care. Lung microbiota has been shown to be involved in the immunity against influenza and is correlated with lung inflammation in numerous chronic respiratory diseases. We therefore aim to analyse the correlation between lung bacteriobiota and influenza ICU mortality

Conditions

Interventions

DIAGNOSTIC_TEST

influenza screening

positive influenza screening

Sponsors & Collaborators

  • University of Bordeaux

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-01
Primary Completion
2020-04-30
Completion
2020-04-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04131296 on ClinicalTrials.gov